drugset / Trial / NCT05505812
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer
Phase 0
Not yet recruiting
10 enrolled
The Affiliated Hospital of Qingdao University
Qingdao Sino-Cell Biomedicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced breast cancer.
Timeline
- Start
- 2022-10-08
- Primary completion
- 2023-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-IT101 | Cell therapy | 1e+09 cells | Intravenous |
| Subject | HS-IT101 | Cell therapy | 6e+10 cells | Intravenous |